Naloxegol Health Outcome Post Authorisation Safety Study
An Observational Post-Authorisation Safety Study (PASS) of MOVENTIG® (Naloxegol) Among Patients Aged 18 Years and Older Treated With Opioids Chronically
Sponsor: Kyowa Kirin Pharmaceutical Development Ltd
Terminated
Not feasible to reach the required number of patient cases by the defined end of data collection milestone (Q4 2022) knowing that the study completion was planned by the end of 2023
Listed as NCT02813369, this observational or N/A phase trial focuses on Opioid Induced Constipation and remains terminated or withdrawn. Sponsored by Kyowa Kirin Pharmaceutical Development Ltd, it has been updated 13 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Aug 2024 — Sep 2024 [monthly]
Terminated
-
Jul 2024 — Aug 2024 [monthly]
Terminated
-
Mar 2024 — Jul 2024 [monthly]
Terminated
Status: Unknown Status → Terminated
-
Apr 2023 — Mar 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
▶ Show 8 earlier versions
-
Apr 2021 — Apr 2023 [monthly]
Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Recruiting
-
Oct 2019 — Jan 2021 [monthly]
Recruiting
-
Jun 2018 — Oct 2019 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Recruiting NA
-
Mar 2017 — Mar 2018 [monthly]
Recruiting NA
-
Jan 2017 — Mar 2017 [monthly]
Recruiting NA
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kyowa Kirin Pharmaceutical Development Ltd
For direct contact, visit the study record on ClinicalTrials.gov .